(0.16%) 5 477.90 points
(0.04%) 39 128 points
(0.49%) 17 805 points
(0.06%) $80.88
(-5.04%) $2.62
(-0.90%) $2 309.80
(-0.36%) $28.77
(2.90%) $1 015.00
(0.35%) $0.936
(0.64%) $10.67
(0.51%) $0.792
(0.87%) $88.25
-5.20% $ 3.10
Live Chart Being Loaded With Signals
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States...
Stats | |
---|---|
Volumen de hoy | 902 |
Volumen promedio | 1 889 |
Capitalización de mercado | 19.86M |
EPS | $0 ( Q3 | 2023-09-30 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.67 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.203 (6.55%) |
Volumen Correlación
PHAXIAM Therapeutics S.A. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
PHAXIAM Therapeutics S.A. Correlación - Moneda/Commodity
PHAXIAM Therapeutics S.A. Finanzas
Annual | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-2.91M (0.00 %) |
EPS: | $-0.00730 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-2.91M (0.00 %) |
EPS: | $-0.00730 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico